Skip to main content
Equibles
STXS logo

STXS · Stereotaxis, Inc.

Track STXS — free

Use STXS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research STXS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.29 -0.01 (-0.77%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$129.26M
Shares
100.20M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.29 Open$1.33 Day$1.28–1.35 52W close$1.26–3.57 Avg vol 30d603K Short int5.1M · 5.0% float · 9.9d Short vol63% Last earningsAug 11, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 12

Up next

Next earnings call
Nov 23, 2026 Est · unconfirmed · in 10 wks
Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$30.07M
Trailing 12 months
Net income (TTM)
−$22.32M
Trailing 12 months
Revenue growth YoY
-12.8%
Year over year
Operating margin
-75.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+13.7%
Year over year · more shares
Price change (1Y)
-55.2%
Trailing year
Short interest
5.0%
Latest settlement · 9.9 days to cover
View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 11, 2026
Q2 FY26

TL;DR. Stereotaxis reported Q2 revenue of $7.7M and provided quarterly guidance of ~$7M/$8M in recurring revenue and ~$3M/$3M in system revenue for Q3/Q4, targeting cash flow profitability in 1H 2027, while highlighting early commercial wins including the first US GenesisX purchase, initial Synchrony system sales, and robotic catheter revenue surpassing $1M with 270% sequential growth.

Bullish
  • + Management issued quarterly guidance for strong recurring revenue ramp to ~$7M in Q3 and ~$8M in Q4, and targets cash flow profitability in 1H 2027.
  • + Received and shipped multiple Synchrony systems following FDA clearance in April, with a path to over $1M per quarter and several hospitals considering standardizing their cath labs on Synchrony.
  • + Company maintains a clean balance sheet with $10.5M cash, no debt, and confidence in advancing strategy without substantial dilution.
Bearish
  • − Q2 system revenue of $1.5M declined sharply year-over-year due to no robotic system delivery in the quarter.
  • − Operating loss and net loss widened year-over-year, and adjusted operating loss and adjusted net loss also increased.
  • − Gross margins remain depressed at 58% overall (66% recurring, 29% system) due to low manufacturing volume, expected to persist over the next few quarters.
  • − Robotic catheter growth remains supply-constrained with a backlog of catheter orders, limiting near-term revenue recognition.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −33%
below
Price vs 50-day avg −11%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 1%
near low
Momentum
relative strength
Very Weak
1-month return −7%
trailing
6-month return −28%
trailing
YTD return −44%
this year
Relative strength −46%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +11 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.04% of float · ▼ -6.2% MoM · 9.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
107 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Strong
Revenue growth −6%
Y/Y
Gross margin 58%
expanding
EPS growth +17%
Y/Y
Balance sheet $41.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 53%
annualized · 1-yr
Max drawdown −65%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 11, 2026
third quarter of this year
Recurring revenue $7M
System revenue $3M
fourth quarter of this year
System revenue $3M
Prior guidance period ended · from the 8-K filed Aug 12, 2024
Cash and no debt · end this year $13M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−33% Bearish
Price vs 50-day avg
−11% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +11 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.04% of float · ▼ -6.2% MoM · 9.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
107 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 1% Range high $4
vs 200-day avg -33% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
STXS
Stereotaxis, Inc.
this stock
$129.26M -43.9% -5.8% — 5.0%
ISRG
Intuitive Surgical Inc
 $130.41B -34.8% +20.5% 42.4 2.2%
BDX
Becton Dickinson & Co
 $48.44B — +8.2% — 3.9%
MDLN
Medline Inc.
 $42.77B -22.5% +11.5% — 3.0%
ALC
Alcon Inc
 $31.92B -16.2% +10.5% — 3.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
107
% held
42.5%
Net QoQ
-470.7K sh
Top holder
DAFNA Capital Management…
Held Float
View
Held by Funds
Fund positions
82
View
Short & Settlement
Short Interest Falling
Shares short
5.1M
Days to cover
9.9d
Change
-332.7K sh
View
Short Volume
Short vol %
63%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
893
Value
$1.2K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
52.6%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$32.4M
Net income (FY)
$-21.6M
EPS diluted
$-0.25
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 12, 2026
This year
12
View
Exempt Offerings
Offering
Indefinite
Filed
Aug 15, 2024
View
Earnings & Events
Earnings Calls
Last call
Aug 11, 2026
View

Performance

5D 20D 120D MTD YTD
STXS -7.2% -6.5% -27.9% -10.4% -43.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -6.0% -4.8% -45.8% -10.1% -56.0%
Key facts CIK 1289340 CUSIP 85916J409 13F (30d) 30 filings 30 filers Visit website Investor relations